Methocarbamol

There is no experience in the use of methocarbamol during pregnancy. Animal studies have not established safe use of methocarbamol with regard to effects upon pregnancy, embryonic/foetal development, parturition and postnatal development. The potential risk for humans is not known. Therefore, methocarbamol should not be used during pregnancy.

Safe use of injectable methocarbamol has not been established with regard to possible adverse effects upon fetal development. There have been reports of fetal and congenital abnormalities following in utero exposure to methocarbamol. Therefore, injectable methocarbamol should not be used in women who are or may become pregnant and particularly during early pregnancy unless in the judgment of the physician the potential benefits outweigh the possible hazards.

It is not known whether methocarbamol and/or its metabolites pass into human milk. Methocarbamol and/or its metabolites are excreted into the milk of lactating dogs. Therefore methocarbamol should not be used by breast-feeding women.

Long-term studies to evaluate the carcinogenic potential of methocarbamol have not been performed. No studies have been conducted to assess the effect of methocarbamol on mutagenesis or its potential to impair fertility.

Animal reproductive studies have not been conducted with methocarbamol.

Methocarbamol has moderate influence on the ability to drive and use machines as methocarbamol may cause dizziness or drowsiness, especially if other medications capable of causing drowsiness are also being taken. Possible undesirable effects of methocarbamol may affect the patient’s ability to drive and use machines.